OpiAID
OpiAID is a pioneering data science company dedicated to advancing treatment for substance use disorder (SUD) through innovative solutions that empower clinicians in Medically Assisted Treatment (MAT). By integrating Electronic Health Record (EHR) data with real-time biometric data, OpiAID enhances treatment outcomes, increases clinic revenue, and reduces costs for payors. Their AI-driven platform provides actionable insights and personalized treatment plans, ensuring safer and more effective recovery journeys for patients. OpiAID's commitment to innovation and research positions it as a leader in the opioid treatment market, aiming to redefine care for those in recovery.
OpiAID
OpiAID is a pioneering data science company dedicated to advancing treatment for substance use disorder (SUD) through innovative solutions that empower clinicians in Medically Assisted Treatment (MAT). By integrating Electronic Health Record (EHR) data with real-time biometric data, OpiAID enhances treatment outcomes, increases clinic revenue, and reduces costs for payors. Their AI-driven platform provides actionable insights and personalized treatment plans, ensuring safer and more effective recovery journeys for patients. OpiAID's commitment to innovation and research positions it as a leader in the opioid treatment market, aiming to redefine care for those in recovery.
TL;DR
Headquarters: Wilmington, North Carolina, USA
Product: AI-enabled recovery intelligence platform integrating EHR with wrist-worn biometric devices
Founder & CEO: David Reeser
Founded: 2018
Recent funding: Grants including a May 2023 NIDA grant
Company Overview
Problem Domain
Improving treatment and monitoring for opioid use disorder and other substance use disorders through data-driven clinical decision support.
Founded
2018
Industry
Healthtech / Digital health (SUD treatment, wearable monitoring)
Funding Track Record
Reported grant (Jan 2020) referenced in funding history
Reported grant (Feb 2021) referenced in funding history
2800000.00
May 2023 NIDA grant reported
Investor Signal
“Grants from government and state programs (including NIDA and a One North Carolina Small Business Program award)”